Bone health and prevalent fractures in women with polycystic ovary syndrome: a meta-analysis and endocrine-context pathophysiology review

References

• Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018;89(3):251–268. DOI:10.1111/cen.13795
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. DOI:10.1016/j.fertnstert.2003.10.004
   Web of Science ®Google Scholar
• Prezelj J, Kocijancic A. Bone mineral density in hyperandrogenic amenorrhoea. Calcif Tissue Int. 1993;52(6):422–424.
   PubMed Web of Science ®Google Scholar
• Nicodemus KK, Folsom AR, Anderson KE. Menstrual history and risk of hip fractures in postmenopausal women. The Iowa women’s health study. Am J Epidemiol. 2001;153(3):251–255.
   PubMed Web of Science ®Google Scholar
• Buchanan JR, Hospodar P, Myers CA, et al. Effect of excess endogenous androgens on bone density in young women. J Clin Endocrinol Metab. 1988;67(5):937–943. DOI:10.1210/jcem-67-5-937
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2(1):16057. DOI:10.1038/nrdp.2016.57
   PubMed Web of Science ®Google Scholar
• Langsetmo L, Hitchcock CL, Kingwell EJ, et al. Physical activity, body mass index and bone mineral density-associations in a prospective population-based cohort of women and men: the Canadian Multicentre Osteoporosis Study (CaMos). Bone. 2012;50(1):401–408. DOI:10.1016/j.bone.2011.11.009
   PubMed Web of Science ®Google Scholar
• Prieto-Alhambra D, Premaor MO, Fina AF, et al. The association between fracture and obesity is site-dependent: a population-based study in postmenopausal women. J Bone Mineral Res. 2012;27(2):294–300. DOI:10.1002/jbmr.1466
   PubMed Web of Science ®Google Scholar
• Johansson H, Kanis JA, Oden A, et al. A meta-analysis of the association of fracture risk and body mass index in women. J Bone Mineral Res. 2014;29(1):223–233. DOI:10.1002/jbmr.2017
   PubMed Web of Science ®Google Scholar
• Rubin KH, Glintborg D, Nybo M, et al. Fracture risk is decreased in women with polycystic ovary syndrome: a register-based and population-based cohort study. J Bone Mineral Res. 2016;31(4):709–717. DOI:10.1002/jbmr.2737
   PubMed Web of Science ®Google Scholar
• Yang HY, Lee HS, Huang WT, et al. Increased risk of fractures in patients with polycystic ovary syndrome: a nationwide population-based retrospective cohort study. J Bone Miner Metab. 2018;36(6):741–748. DOI:10.1007/s00774-017-0894-8
   PubMed Web of Science ®Google Scholar
• Glintborg D, Hermann AP, Andersen M. Bone mineral density and vitamin D in PCOS and hirsutism. Expert Rev Endocrinol Metab. 2013;8(5):449–459.
   PubMedGoogle Scholar
• Piovezan JM, Premaor MO, Comim FV. Negative impact of polycystic ovary syndrome on bone health: a systematic review and meta-analysis. Hum Reprod Update. 2019;25(5):633–645. DOI:10.1093/humupd/dmz020
   PubMed Web of Science ®Google Scholar
• Li D, Hitchcock CL, Barr SI, et al. Negative spinal bone mineral density changes and subclinical ovulatory disturbances—prospective data in healthy premenopausal women with regular menstrual cycles. Epidemiol Rev. 2014;36(1):137–147. DOI:10.1093/epirev/mxt012
   PubMedGoogle Scholar
• Briden L, Shirin S, Prior JC. The central role of ovulatory disturbances in the etiology of androgenic polycystic ovary syndrome (PCOS)—Evidence for treatment with cyclic progesterone. Drug Discov Today Dis Models. 2020;32(Part B):71–82.
   Google Scholar
• Goshtasebi A, Kalyan S, Liang B, et al. Community dwelling premenopausal women with polycystic ovary syndrome/anovulatory androgen excess (PCOS/AAE) experience more prevalent fractures than regional population-based control women from the BC centre of the Canadian Multicentre Osteoporosis Study (CaMos). J Bone Mineral Res. 2018;33(Suppl 1):S395. Accessed Apr 3, 2023. Available at: https://asbmr.onlinelibrary.wiley.com/toc/15234681/2018/33/S1
   Google Scholar
• Prior JC. Adaptive, reversible, hypothalamic reproductive suppression: more than functional hypothalamic amenorrhea. Front Endocrinol (Lausanne). 2022;13:893889.
   PubMed Web of Science ®Google Scholar
• Li G, Prior JC, Leslie WD, et al. Frailty and risk of fractures in patients with type 2 diabetes. Diabetes Care. 2019;42(4):507–513. DOI:10.2337/dc18-1965
   PubMed Web of Science ®Google Scholar
• Koromani F, Oei L, Shevroja E, et al. Vertebral fractures in individuals with type 2 diabetes: more than skeletal complications alone. Diabetes Care. 2020;43(1):137–144. DOI:10.2337/dc19-0925
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Stribrska L, Ramsey EE, et al. Androgen receptors in osteoblast-like cell lines. Calcif Tissue Int. 1991;49(3):183–187. DOI:10.1007/BF02556115
   PubMed Web of Science ®Google Scholar
• Khosla S. New insights into androgen and estrogen receptor regulation of the male skeleton. J Bone Mineral Res. 2015;30(7):1134–1137.
   PubMed Web of Science ®Google Scholar
• Notelovitz M. Androgen effects on bone and muscle. Fertil Sterility. 2002;77(Suppl 4):S34–41.
   PubMed Web of Science ®Google Scholar
• Mills EG, Yang L, Nielsen MF, et al. The relationship between bone and reproductive hormones beyond estrogens and androgens. Endocr Rev. 2021;42(6):691–719. DOI:10.1210/endrev/bnab015
   PubMed Web of Science ®Google Scholar
• Kassanos D, Trakakis E, Baltas CS, et al. Augmentation of cortical bone mineral density in women with polycystic ovary syndrome: a peripheral quantitative computed tomography (pQCT) study. Hum Reprod. 2010;25(8):2107–2114. DOI:10.1093/humrep/deq149
   PubMed Web of Science ®Google Scholar
• Rosato E, Sciarra F, Anastasiadou E, et al. Revisiting the physiologic role of androgens in women. Expert Rev Endocrinol Metab. 2022;17(6):547–561. DOI:10.1080/17446651.2022.2144834
   PubMed Web of Science ®Google Scholar
• Horstman AM, Dillon EL, Urban RJ, et al. The role of androgens and estrogens on healthy aging and longevity. J Gerontol A Biol Sci Med Sci. 2012;67(11):1140–1152. DOI:10.1093/gerona/gls068
   PubMed Web of Science ®Google Scholar
• Sun Y, Wang W, Guo Y, et al. High copper levels in follicular fluid affect follicle development in polycystic ovary syndrome patients: population-based and in vitro studies. Toxicol Appl Pharmacol. 2019;365:101–111.
   PubMed Web of Science ®Google Scholar
• Kalyan S, Prior JC. Bone changes and fracture related to menstrual cycles and ovulation. Crit Rev Eukaryot Gene Expr. 2010;20(3):213–233.
   PubMed Web of Science ®Google Scholar
• Burgers JA, Fong SL, Louwers YV, et al. Oligoovulatory and anovulatory cycles in women with polycystic ovary syndrome (PCOS): what’s the difference? J Clin Endocrinol Metab. 2010;95(12):E485–9.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Muthusami S. Hormonal alterations in PCOS and its influence on bone metabolism. J Endocrinol. 2017;232(2):R99–113.
   PubMed Web of Science ®Google Scholar
• Berberoglu Z. Insight into bone metabolism and skeletal mass in polycystic ovary syndrome. EMJ Reproductive Health. 2015;1(1):46–53.
   Google Scholar
• Kujanpaa L, Arffman RK, Pesonen P, et al. Women with polycystic ovary syndrome are burdened with multimorbidity and medication use independent of body mass index at late fertile age: a population-based cohort study. Acta Obstet Gynecol Scand. 2022;101(7):728–736.
   PubMed Web of Science ®Google Scholar
• MacNamara P, O’Shaughnessy C, Manduca P, et al. Progesterone receptors are expressed in human osteoblast-like cell lines and in primary human osteoblast cultures. Calcif Tissue Int. 1995;57(6):436–441.
   PubMed Web of Science ®Google Scholar
• Prior JC, Vigna YM, Schechter MT, et al. Spinal bone loss and ovulatory disturbances. N Engl J Med. 1990;323(18):1221–1227.
   PubMed Web of Science ®Google Scholar
• Prior JC, Vigna YM, Barr SI, et al. Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am j med. 1994;96(6):521–530. DOI:10.1016/0002-9343(94)90092-2
   PubMed Web of Science ®Google Scholar
• Schmidt J, Brännström M, Landin-Wilhelmsen K, et al. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab. 2011;96(7):2178–2185. DOI:10.1210/jc.2010-2959
   PubMed Web of Science ®Google Scholar
• Goshtasebi A, Berger C, Prior JC, et al. Peak perimenopausal lumbar spine BMD is related to fracture risk in a population-based cohort of midlife women in the Canadian Multicentre Osteoporosis Study (CaMos). Am Soc Bone Miner Res Annual Meeting. 2019. SUN653.
   Google Scholar
• Kalyan S, Patel MS, Kingwell E, et al. Competing factors link to bone health in polycystic ovary syndrome: chronic low-grade inflammation takes a toll. Sci Rep. 2017;7(1):3432.
   PubMedGoogle Scholar
• Buchanan JR, Myers C, Lloyd T, et al. Determinants of peak trabecular bone density in women: the role of androgens, estrogen and exercise. J Bone Mineral Res. 1988;3(6):673–680.
   PubMed Web of Science ®Google Scholar
• Blümel JE, Arteaga E, Aedo S, et al. Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study. Gynecol Endocrinol. 2020;36(5):421–425.
   PubMed Web of Science ®Google Scholar
• Pernicova I, Kelly S, Ajodha S, et al. Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Diabetes Endocrinol. 2020;8(4):278–291.
   PubMed Web of Science ®Google Scholar
• van Hooff MH, Voorhorst FJ, Kaptein MB, et al. Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 year old adolescents. Hum Reprod. 1999;14(9):2223–2229.
   PubMed Web of Science ®Google Scholar
• Brajic TS, Berger C, Schlammerl K, et al. Combined hormonal contraceptives use and bone mineral density changes in adolescent and young women in a prospective population-based Canada-wide observational study. J Musculoskelet Neuronal Interact. 2018;18(2):227–236.
   PubMed Web of Science ®Google Scholar
• Kalyan S, Goshtesabi A, Sarray S, et al. Assessing C reactive protein/albumin ratio as a new biomarker for polycystic ovary syndrome: a case-control study of women from Bahraini medical clinics. BMJ Open. 2018;8(10):e021860.
   PubMed Web of Science ®Google Scholar
• Moran LJ, Thomson RL, Buckley JD, et al. Steroidal contraceptive use is associated with lower bone mineral density in polycystic ovary syndrome. Endocrine. 2015;50(3):811–815.
   PubMed Web of Science ®Google Scholar
• Goshtasebi A, Subotic Brajic T, Scholes D, et al. Adolescent use of combined hormonal contraception and peak bone mineral density accrual: a meta-analysis of international prospective controlled studies. Clin Endocrinol (Oxf). 2019;90(4):517–524.
   PubMed Web of Science ®Google Scholar
• Cooper C, Hannaford P, Croft P, et al. Oral contraceptive pill use and fractures in women: a prospective study. Bone. 1993;14(1):41–45.
   PubMed Web of Science ®Google Scholar
• Vessey M, Mant J, Painter R. Oral contraception and other factors in relation to hospital referral for fracture - findings in a large cohort study. Contraception. 1998;57(4):231–235.
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Zamberlan N, et al. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab. 1999;84(4):1250–1254.
   PubMed Web of Science ®Google Scholar
• Adolf C, Braun LT, Fuss CT, et al. Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism. Endocrine. 2020;69(3):625–633.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporosis Int. 2007;18(8):1033–1046.
   PubMed Web of Science ®Google Scholar
• Schmidt J, Dahlgren E, Brännström M, et al. Body composition, bone mineral density and fractures in late postmenopausal women with polycystic ovary syndrome - a long-term follow-up study. Clin Endocrinol (Oxf). 2012;77(2):207–214.
   PubMed Web of Science ®Google Scholar
• Ross PD, Genant HK, Davis JW, et al. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporosis Int. 1993;3(3):120–126.
   PubMed Web of Science ®Google Scholar
• Goshtasebi A, Berger C, Barr SI, et al. Adult premenopausal bone health related to reproductive characteristics-population-based data from the Canadian Multicentre Osteoporosis Study (CaMos). Int J Environ Res Public Health. 2018;15(5):1023.
   PubMed Web of Science ®Google Scholar
• Comim FV, Marchesan LQ, Copes RM, et al. Increased risk of humerus and lower leg fractures in postmenopausal women with self-reported premenopausal hirsutism and/or oligomenorrhea. Eur J Obstet Gynecol Reprod Biol. 2016;203:162–166.
   PubMed Web of Science ®Google Scholar
• Zong Z, Kalyan S, Andres C, et al. Prevalence of ocular anomalies is increased in women with polycystic ovary syndrome-exploration of association with PAX6 genotype. Ophthalmic Genet. 2022;43(3):340–343.
   PubMed Web of Science ®Google Scholar
• Kreiger N, Tenenhouse A, Joseph L, et al. Research notes: the Canadian Multicentre Osteoporosis Study (camos): background, rationale, methods. Can J Aging. 1999;18(3):376–387.
   Web of Science ®Google Scholar
• Zhou W, Langsetmo L, Berger C, et al. Normative bone mineral density z-scores for Canadians aged 16 to 24 years: the Canadian multicenter osteoporosis study. J Clin Densitom. 2010;13(3):267–276.
   PubMed Web of Science ®Google Scholar
• Berger C, Goltzman D, Langsetmo L, et al. Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Mineral Res. 2010;25(9):1948–1957.
   PubMed Web of Science ®Google Scholar
• Prior JC, Hitchcock CL, Vigna YM, et al. Premenopausal trabecular bone loss is associated with a family history of fragility fracture. Geburtshilfe Frauenheilkd. 2016;76(8):895–901.
   PubMed Web of Science ®Google Scholar
• Bedford JL, Prior JC, Barr SI. A prospective exploration of cognitive dietary restraint, subclinical ovulatory disturbances, cortisol and change in bone density over two years in healthy young women. J Clin Endocrinol Metab. 2010;95(7):3291–3299.
   PubMed Web of Science ®Google Scholar
• Rich-Edwards JW, Goldman MB, Willett WC, et al. Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol. 1994;171(1):171–177.
   PubMed Web of Science ®Google Scholar
• Langsetmo L, Hanley DA, Prior JC, et al. Dietary patterns and incident low-trauma fractures in postmenopausal women and men aged ≥ 50 y: a population-based cohort study. Am J Clin Nutr. 2011;93(1):192–199.
   PubMed Web of Science ®Google Scholar
• LaMonte MJ, Wactawski-Wende J, Larson JC, et al. Association of physical activity and fracture risk among postmenopausal women. JAMA Netw Open. 2019;2(10):e1914084.
   PubMed Web of Science ®Google Scholar
• Gebel K, Pont S, Ding D, et al. Patterns and predictors of sitting time over ten years in a large population-based Canadian sample: findings from the Canadian Multicentre Osteoporosis Study (CaMos). Prev Med Rep. 2017;5:289–294.
   PubMedGoogle Scholar
• Prior JC, Seifert-Klauss VR, Giustini D, et al. Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy - a systematic review and meta-analysis of controlled trials with direct randomization. J Musculoskelet Neuronal Interact. 2017;17(3):146–154.
   PubMed Web of Science ®Google Scholar
• Anderl C, de Wit AE, Giltay EJ, et al. Association between adolescent oral contraceptive use and future major depressive disorder: a prospective cohort study. J Child Psychol Psychiatr. 2022;63(3):333–341.
   PubMed Web of Science ®Google Scholar
• Anderl C, Li G, Chen FS. Oral contraceptive use in adolescence predicts lasting vulnerability to depression in adulthood. J Child Psychol Psychiatr. 2020;61(2):148–156.
   PubMed Web of Science ®Google Scholar
• Skovlund CW, Mørch LS, Kessing LV, et al. Association of hormonal contraception with depression. JAMA Psychiatry. 2016;73(11):1154–1162.
   PubMed Web of Science ®Google Scholar
• Barr SI, Janelle KC, Prior JC. Energy intakes are higher during the luteal-phase of ovulatory menstrual cycles. Am J Clin Nutr. 1995;61(1):39–43.
   PubMed Web of Science ®Google Scholar